Why ‘Normal’ Cholesterol Doesn’t Mean Low Risk

As a functional medicine physician, one of the most common misconceptions I see in my practice is the belief that a “normal” cholesterol report is a clean bill of health for the heart.  

The truth is, nearly 50% of individuals who suffer a heart attack or stroke, their cholesterol levels were considered “normal” by standard measures. This isn’t a failure of the patient; it’s a failure of an outdated and incomplete model of risk assessment.  

My goal is to replace your confusion and health information anxiety with clarity and empowerment, giving you an actionable plan to understand and address your true cardiovascular health. 

Why Normal Cholesterol Levels Don’t Always Mean Low Heart Disease Risk 

For decades, we’ve been taught to fear cholesterol, particularly LDL or “bad” cholesterol. If this has never quite made sense to you, you’re not missing something obvious—this is genuinely complex biology that gets oversimplified. While it plays a role, focusing on it exclusively is like trying to understand a complex movie by watching only one scene. Cardiovascular disease is a multifaceted process, and a single number can’t tell the whole story.  

At this point, you may be wondering “what else should I be considering when it comes to my heart health?”. 

Insulin Resistance and Its Role in Heart Disease 

If there is one hidden driver of heart disease I wish every person understood, it’s insulin resistance. This metabolic condition is a primary, yet often overlooked, root cause of cardiovascular events. It is far more than a stepping stone to type 2 diabetes; it is an independent and powerful risk factor for heart disease itself. This is not a fringe theory but a well-established scientific fact, confirmed by numerous studies including a major 2018 review in Cardiovascular Diabetology that detailed the clear “association between insulin resistance and the development of cardiovascular disease” (Ormazábal et al., 2018). 

How Insulin Resistance Develops Before High Blood Sugar 

Many people believe that as long as their blood sugar or HbA1c is normal, they don’t have a problem. This is a critical misunderstanding. Insulin resistance begins long before blood sugar rises. It starts when your body’s cells, particularly in your muscles, liver, and fat, stop responding effectively to the hormone insulin. In a desperate attempt to keep your blood sugar in the normal range, your pancreas compensates by pumping out more and more insulin. 

This state of high circulating insulin, known as hyperinsulinemia, is the first and most damaging stage. It can persist for years or even decades while your fasting glucose remains perfectly normal. This high insulin level is what drives the damage. Research, such as a 2023 study in the Journal of International Medical Research, details how this excess insulin directly harms the vascular system, promoting dysfunction in the endothelial lining and smooth muscle cells of the arteries, long before high blood sugar ever appears on a lab test (Kosmas et al., 2019). 

The Link Between Insulin Resistance and Unhealthy Cholesterol Patterns 

High insulin levels send a direct signal to your liver that creates a perfect storm for heart disease. This condition is called atherogenic dyslipidemia, and it’s a classic signature of insulin resistance. Here’s how it works: 

• High Triglycerides: Insulin tells the liver to ramp up production of VLDL (very-low-density lipoprotein), which is rich in triglycerides. 

• Low HDL (“Good”) Cholesterol: The same processes that raise triglycerides also lead to the breakdown of protective HDL cholesterol. 

• Small, Dense LDL Particles: Most importantly, this metabolic environment causes a qualitative shift in your LDL particles. They transform from large, fluffy, relatively benign “beach balls” into small, dense, highly aggressive “BBs” that are much more likely to penetrate the artery wall and initiate plaque formation. 

Chronic Inflammation and Cardiovascular Health 

If insulin resistance is the metabolic engine of heart disease, chronic, low-grade inflammation is the fire that fuels it. We are not talking about the acute inflammation of a sprained ankle, but a persistent, smoldering fire throughout the body that damages tissues, including the delicate lining of our arteries. The most common and useful way we measure this systemic inflammation in clinical practice is with a blood test called high-sensitivity C-reactive protein (hs-CRP). 

How Chronic Inflammation Increases Heart Disease Risk 

Chronic inflammation increases heart disease risk through several mechanisms. It makes the endothelial lining of the arteries “leaky” and “sticky,” which allows more atherogenic particles like LDL to infiltrate the artery wall. Once inside, inflammation promotes the oxidation of these LDL particles, a critical step that transforms them into a major component of plaque. 

Furthermore, as a 2021 review in Pharmacological Research explains, inflammation makes existing plaques unstable and more prone to rupture, which is the direct cause of most heart attacks (Goswami et al., 2021). Addressing the root causes of this inflammation—be it from a poor diet, gut infections, chronic stress, or toxins—is therefore a non-negotiable part of any true cardiovascular prevention strategy. It’s about putting out the fire, not just cleaning up the smoke. 

Understanding Cholesterol Beyond LDL and Total Cholesterol 

Once we accept the limitations of standard testing, we can begin to explore the advanced markers that give us a far more accurate picture of risk. This is where we move beyond the simple LDL-C number and start asking more sophisticated questions about the quality and quantity of the particles carrying that cholesterol. This is how we truly answer the question, “what is a better predictor of heart disease than cholesterol?” 

Small dense LDL particles and cardiovascular risk 

As we discussed in the context of insulin resistance, not all LDL particles are created equal. The smaller, denser subtype (sdLDL) is significantly more dangerous. Think of it like BBs versus beach balls. Because of their small size, sdLDL particles can more easily slip through the endothelial lining and get trapped in the artery wall. They also persist in the circulation longer and are more susceptible to oxidation, making them highly atherogenic. 

The data is clear: an abundance of small LDL particles is associated with a two- to three-fold increase in the risk of coronary heart disease. This shift in particle quality is a critical piece of hidden heart disease risk that a standard panel completely misses. 

ApoB Testing as a Better Predictor of Heart Disease 

If you remember only one thing from this article, let it be this: Apolipoprotein B (ApoB) is the single most important number to know to understand your risk from cholesterol. ApoB is a protein found on the surface of every single atherogenic (plaque-causing) lipoprotein, including LDL, VLDL, and their remnants. There is exactly one ApoB molecule per particle. 

Therefore, measuring ApoB is a direct count of the total number of potentially dangerous particles in your bloodstream (Behbodikhah et al., 2021).  

This is powerfully confirmed by the 2024 review in the AHA journal Circulation, which concluded that ApoB measurement consistently outperforms LDL-C measurement in predicting cardiovascular risk (de Oliveira-Gomez, et al., 2024). Having a high number of particles (a high ApoB), even if they are not carrying much cholesterol (a normal LDL-C), is what drives risk. 

Advanced Cardiovascular Markers That Reveal Hidden Risk 

A comprehensive cardiovascular assessment in a functional medicine setting goes beyond even ApoB. We use a panel of markers to build a complete picture of metabolic health, inflammation, and genetic predispositions. This is the toolkit that allows us to look “under the hood” and detect dysfunction at its earliest, most reversible stage. A key marker in this panel is Lipoprotein(a), or Lp(a), a largely genetic particle that is a significant and independent risk factor.  

Fasting Insulin as an Early Warning Sign 

As discussed, high insulin precedes high blood sugar by years. A fasting insulin level is a direct measurement of hyperinsulinemia and one of the most sensitive and earliest markers of insulin resistance. In my practice, it is a non-negotiable test. An optimal fasting insulin level is generally below 8 µIU/mL, and ideally below 5. Seeing this number creep up is a critical early warning sign that allows for intervention long before any permanent damage is done, a concept supported by research into the early vascular effects of insulin resistance (Kosmas et al., 2019). 

Triglyceride-to-HDL Ratio and Metabolic Health 

This is a simple yet powerful calculation you can do yourself using the numbers from your standard lipid panel. Simply divide your triglyceride level by your HDL level. This ratio serves as an excellent proxy for insulin resistance and the presence of those dangerous small, dense LDL particles. A ratio below 2.0 is considered good, while a ratio below 1.0 is optimal. A high ratio is a major red flag for poor metabolic health and atherogenic dyslipidemia (Ormazábal et al., 2018).  

Homocysteine and its Impact on Vascular Function 

Homocysteine is an amino acid that can accumulate in the blood and act as a toxin to the endothelial lining of the arteries, damaging them and promoting inflammation and blood clotting. Elevated levels are often a sign of inadequate levels of key B vitamins, particularly folate, B12, and B6, which are required to properly metabolize it. Testing for homocysteine allows us to identify a modifiable risk factor that is directly tied to nutrient status—a core principle of functional medicine. 

How Advanced Labs Detect Risk Earlier than Standard Panels 

The power of this advanced panel—ApoB, fasting insulin, hs-CRP, Lp(a), homocysteine, and others—is that it shifts the focus from a downstream symptom (high cholesterol) to the upstream root causes and mechanisms of disease. It allows us to see the particle burden, the metabolic dysfunction, the inflammation, and the genetic predispositions. 

This comprehensive view allows for highly personalized and targeted interventions at a much earlier stage, empowering us to prevent the fire from starting, rather than just trying to manage the smoke. The broader cardiology community is increasingly recognizing this need to look further, as reflected in ongoing discussions and updates. 

Genetics, Family History, and Heart Disease Risk 

A strong family history of heart disease is a significant risk factor that should never be ignored. Often, this is driven by inherited genetic traits. One of the most important of these is Lipoprotein(a), or Lp(a). Lp(a) is a type of lipoprotein whose level in the blood is almost entirely determined by your genes. A landmark 2022 consensus statement from the European Atherosclerosis Society confirmed that extensive genetic and epidemiological studies “strongly support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes” (Kronenberg et al., 2022). Crucially, they note that this risk is present even at very low levels of LDL cholesterol, making it a perfect example of a hidden risk factor.  

How Lifestyle and Metabolism Influence Genetic Risk 

Receiving a diagnosis of high Lp(a) or having a strong family history can feel like a life sentence, but this is where the functional medicine approach provides hope and empowerment. There’s a saying we often use: “Genetics loads the gun, but lifestyle pulls the trigger.” While you cannot change the genes that give you high Lp(a), you can absolutely change the environment in which those genes operate. 

You can profoundly lower your overall cardiovascular risk by aggressively optimizing every other modifiable factor. This means doubling down on the strategies that improve insulin sensitivity (Ormazábal et al., 2018), reduce chronic inflammation (Henei et al., 2022), and lower your total atherogenic particle burden (ApoB). By creating a metabolically healthy, low-inflammation internal environment, you make it much harder for your genetic predisposition to express itself as disease. 

How to Reduce Cardiovascular Risk Before Disease Develops 

Understanding your true risk is the first step. The second, and most important, is taking targeted action. The beauty of the functional medicine approach is that the solutions are not just about taking a pill to lower a number; they are about restoring health to the entire system. This is the actionable plan that moves you from being a passive recipient of a diagnosis to the active creator of your long-term health. 

Identifying early leverage points for heart health 

Based on everything we’ve discussed, the most powerful leverage points for preventing cardiovascular disease before it starts are clear: 

• Improve Insulin Sensitivity: This is the master lever for metabolic health. 

• Reduce Chronic Inflammation: This quenches the fire that damages arteries. 

• Lower Atherogenic Particle Burden: This reduces the number of “invaders” trying to get into your artery wall, best measured by ApoB. 

Nutrition, movement, sleep, and stress in cardiovascular prevention 

• Nutrition: The most effective diet for heart health is one that stabilizes blood sugar and reduces inflammation. This means a whole-foods diet rich in fiber, phytonutrients, and healthy fats, while being low in processed carbohydrates, sugar, and industrial seed oils. A Mediterranean-style eating pattern is a well-researched template. Working with a Nutritionist can help as you implement diet changes. 

• Movement: The goal is to improve insulin sensitivity and cardiovascular fitness. A combination of aerobic exercise (like brisk walking, cycling, or swimming) and resistance training to build and maintain muscle mass is the ideal combination. 

• Sleep: This is non-negotiable. Prioritizing 7-9 hours of quality sleep is crucial for metabolic health. Inadequate sleep has been shown to increase insulin resistance, inflammation, and hunger hormones, directly undermining your efforts. 

• Stress: Chronic stress drives high cortisol, which in turn fuels inflammation and insulin resistance. Implementing a daily stress-reduction practice—whether it’s meditation, deep breathing, yoga, or time in nature—is a critical component of managing inflammation and protecting your heart (Goswami et al., 2021). 

Ultimately, all these strategies converge on a single, powerful goal: improving your overall metabolic health. When your body can efficiently process energy, regulate blood sugar, and control inflammation, you are building a foundation of cardiovascular resilience. This is the ultimate upstream solution. By focusing on restoring fundamental metabolic function you are not just lowering risk markers on a lab report; you are creating a system that is inherently less susceptible to the entire process of atherosclerotic disease (Henei et al., 2022), ensuring your heart functions optimally for the long term. 

This article is for informational purposes only and does not constitute medical advice. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. 

What You’ll Learn in the Affairs of the Heart Virtual Program 

For those who are ready to take the next step and apply this knowledge with expert guidance, our Affairs of the Heart virtual program provides the “how.” This program is the practical application of the principles we’ve discussed. It offers a structured, supportive path to help you implement these changes effectively, providing personalized testing, in-depth interpretation of your unique results, and a comprehensive lifestyle plan to address your specific root causes of cardiovascular risk. It is designed to be the logical next step for anyone who wants to move from knowledge to transformation. 

Register Now! 

Dates: March 10, 17, 24, and 31.

Where: Virtual Sessions

References 

1. Henein, M., Vancheri, S., Longo, G., & Vancheri, F. (2022). The Role of Inflammation in Cardiovascular Disease. International Journal of Molecular Sciences, 23(21), 12906. https://doi.org/10.3390/ijms232112906. 
2. Ormazábal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zúñiga, F. (2018). Association between insulin resistance and the development of cardiovascular disease. Cardiovascular Diabetology, 17(1), 122. https://doi.org/10.1186/s12933-018-0762-4. 
3. Adeva-Andany, M. M., Martínez-Rodríguez, J., González-Lucán, M., Fernández-Fernández, C., & Castro-Quintela, E. (2019). Insulin resistance is a cardiovascular risk factor in humans. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(2), 1449–1455. https://doi.org/10.1016/j.dsx.2019.02.023. 
4. Kosmas, C. E., Bousvarou, M., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023). Insulin resistance and cardiovascular disease. The Journal of International Medical Research, 51(4), 03000605231164548. https://doi.org/10.1177/03000605231164548. 
5. Goswami, S., Dutta, R., & Verma, S. (2021). Management of inflammation in cardiovascular diseases. Pharmacological Research, 172, 105912. https://doi.org/10.1016/j.phrs.2021.105912. 
6. Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021). Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites, 11(10), 690. https://doi.org/10.3390/metabo11100690. 
7. de Lemos, J. A., et al. (2024). Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation, 150(2), 115-118. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.068885. 
8. Kronenberg, F., et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 43(39), 3925–3947. https://www.eas-society.org/page/lipoproteina-consensus-2022/.